PP01.54 High-Dimensional Immunophenotyping of Patients with Localized Non-Small Cell Lung Cancer (NSCLC) Reveals Distinct Immune Cell Subsets Predictive of Disease-Free Survival (DFS) in AFT-16 and LCMC3 Datasets
Back to course
Pdf Summary
Asset Subtitle
Nicholas Eustace
Keywords
IMMUNOME panel
flow cytometry
immune cell subsets
non-small cell lung cancer
immune checkpoint inhibitors
atezolizumab
LCMC3 trial
AFT-16 trial
surface marker combinations
biomarkers
Powered By